By Stephanie A. GagnonSeptember 19, 2018 11:09:23The first clinical trial of the gene therapy is set to begin in the United States in late 2016.
The trial is part of the Global Health Partnership initiative launched by the World Health Organization in 2017 to fight the virus.
The initiative has seen hundreds of scientists, health care professionals, and private and public organizations work together to bring together research, development, and public health.
The first trial is being funded by a total of US$9 million from the National Institutes of Health and the European Commission.
The gene therapy, called LASTR4B, is part.
It targets the gene that causes hepatitis C and is currently approved by the FDA for the treatment of advanced liver disease.
The treatment has not yet been approved for use in patients with cirrhosis of the liver.
The Gene Therapy Trials Program is a $5 billion global effort led by the Global Fund to Advance AIDS, Tuberculosis, and Malaria, which has already received more than $2 billion in US$15.4 billion in grants and other financial support from private foundations.
The US Department of Health & Human Services awarded the program with $1.1 billion in FY 2018, while the European Union gave the program $750 million in 2018.
The Global Fund is the largest and most ambitious of a number of international programs launched by World Health to combat the virus in the early 2000s, including the Global Initiative Against Tubercosis (GIAT) in 2009, the Global Genome Initiative in 2011, and the Global Bio-Genomic Initiative in 2015.
“We’re very proud of the work that’s been done by the global partners and their dedication to bringing this research to the community,” David J. Wolk, director of the Gene Therapy Program at the World Cancer Research Fund, said in a statement.
“We have a lot of work ahead of us to improve the gene delivery, testing, and diagnosis system for this new therapeutic approach.”
The first phase of the trials will be in the U.S.
The FDA has granted approval for the LASTERB gene therapy.
In addition to the first phase, the Gene Therapeutics Trial Network (GTN), which includes the NIH, has approved a second phase of trials with the gene therapies, called the LISTR2B gene treatment, in April 2020.
The GTN has already been approved by five countries, and three additional countries are currently on the verge of approval for LISTERB2B.
The GTN is a consortium of institutes, private companies, and international collaborations that has worked with the FDA to evaluate and develop new drug delivery, screening, and treatment systems.
The consortium includes the National Institute of Allergy and Infectious Diseases, National Institute for Allergy & Infectious Disease, National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute on Aging.
The International Agency for Research on Cancer is part and is working with the GTN.
A total of 21 U.K. clinical trials have already been started, according to the GTM, including one for a gene therapy that targets a protein involved in the process of cell division called ERK1/2, which could be used to treat patients with type 1 diabetes, the disease that causes the majority of hepatitis C cases.
There are currently seven other U. K. trials, with an average of three clinical trials per trial.
The trials have been funded by the NIH National Center for Immunization and Respiratory Diseases, the National Health Service, the Department of Veterans Affairs, the University of Sheffield, and other sources.
The trial is expected to take at least three years to complete.
The clinical trials are part of a Global Health Initiative that includes the Global AIDS Program, which focuses on HIV and hepatitis C, and Global Genomics Initiative, which aims to use genetic research and other methods to prevent the spread of the virus and its associated illnesses.
The Genomics Alliance, an initiative led by researchers at the University for Cancer Research and funded by U. S. and international corporations, is also part of this effort.
The Genomics Consortium, an international consortium of companies working on new gene therapies and diagnostic technologies, is the core of this initiative.